# A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers

> **NCT03096756** · PHASE1 · COMPLETED · sponsor: **Galera Therapeutics, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** GC4702 dry powder
- **DRUG:** GC4702 lipid suspension
- **OTHER:** GC4419 IV
- **OTHER:** Placebo Dry Powder
- **OTHER:** Placebo lipid suspension
- **OTHER:** Fed Condition
- **OTHER:** Fasting Condition
- **DRUG:** GC4702 lipid suspension - Part 2

## Key facts

- **NCT ID:** NCT03096756
- **Lead sponsor:** Galera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-26
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096756, "A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03096756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*